sordellii by THP-1 cells was unknown. Therefore, initial experiments were performed with the CASR-blocking compound fucoidan (1 mg/mL), which almost completely prevented the phagocytosis of FLOURC. sordellii by THP-1 cells (P < 0.001), confirming the importance of CASRs in this process (Fig. 1a). Additionally, when cells were treated with the standard, non-selective CASR-blocking agent dextran sulfate at 0.2 mg/mL, there was an inhibition of 81.6 ± 3.5% of phagocytic activity (P < 0.001),

while the negative control agent chondroitin sulfate had a minimal effect at the same dose (Fig. 1a). Exposure of THP-1 cells to exogenously added PGE2 (0.1 or 1 μm) dose-dependently inhibited the phagocytosis of unopsonized FLUORC. sordellii (Fig. 1b), with an inhibition of 35 ± 12.7% (P < 0.05) JQ1 and 54.7 ± 14.5% (P < 0.01), respectively. The Gαs-coupled EP2 and EP4 receptors are important immunoregulatory receptors on macrophages,[15, 28-30] and THP-1 cells have been reported to express both EP2 and EP4 receptors.[31] We therefore verified that PGE2 could increase cAMP in THP-1 cells, finding a 20 ± 3.7-fold increase (P < 0.0001) with 1 μm PGE2 (Fig. 1c). That both EP2 and EP4 receptors were active in these cells was

supported by an increase in cAMP observed when cells were incubated for 15 min with the selective EP2 or EP4 agonists BFA or L-902,688, respectively (Fig. 2a). The activation of the EP2 receptor see more evoked 1.8-fold and 3.3-fold increases in cAMP with BFA (1 and 10 μμ, respectively), while EP4 stimulation with L-902,688 induced 7.1-fold (P < 0.001) and 5.7-fold (P < 0.05) increases in cAMP (1, 10 μμ, respectively). To further explore EP2 and EP4 activation on THP-1 cell phagocytosis, cells were pre-treated with L-902,688 or BFA for 15 min. It was found that L-902,688 (EP4 agonist) exposure suppressed the capacity of THP-1 cells to ingest unopsonized FLUORC. sordellii, while BFA was effective but not quite as potent (Fig. 2b). EP2 and EP4 antagonists

were used to define the extent to Gemcitabine in vitro which these receptors mediate the actions of PGE2 on THP-1 cells. As indicated in Fig. 2c, cAMP increases provoked by PGE2 were blocked by the EP4 antagonist ONO-AE1-208 but not by the EP2/DP1 antagonist AH6809 (1 μm each). To confirm EP2 and EP4 receptor expression by THP-1 cells, cells were lysed and subjected to immunoblot analysis for the detection of these receptors. A band at the expected molecular weight of ~52 kDa was observed for the EP2 receptor, but as evidenced in Fig. 2d, several larger bands were also detected, which are of uncertain significance. A single band at the expected 65 kDa was detected for EP4 (Fig. 2e). Because the EP2 immunoblot result was inconclusive, experiments were conducted to determine mRNA expression levels of EP2 and EP4 using quantitative real-time PCR. RNA was isolated, cDNA was reverse transcribed, and real-time PCR was performed for EP2 and EP4. We found significantly higher expression of EP4 compared with EP2 by THP-1 cells (P < 0.